Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
Recruiting · NCT05879367 · Registry updated 2025-06-25Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioblastoma, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 1 | 2025-06-25 | NCT05879367 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Orbus Therapeutics, Inc. | 1 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Brown University Health/Rhode Island Hospital | Providence | United States | 1 |
| Columbia University Medical Center - Herbert Irving Pavilion | New York | United States | 6 |
| Duke University | Durham | United States | 160 |
| Henry Ford Hospital | Detroit | United States | 326 |
| The Cleveland Clinic | Cleveland | United States | 26 |
| University of Alabama at Birmingham | Birmingham | United States | 247 |
| University of Utah, Huntsman Cancer Institute | Salt Lake City | United States | 8 |
| UT MD Anderson Cancer Center | Houston | United States | 204 |